GI Supply has secured clearance from the Food and Drug Administration (FDA) for its EverLift submucosal lifting agent in a 10ml syringe.
The new device is intended for the lift of polyps, adenomas, early-stage cancers, and other gastrointestinal lesions before excising with a snare or other suitable endoscopic devices.
EverLift is the only pre-filled submucosal lifting agent currently available in the market with 5ml and 10ml presentations.
It offers physicians the flexibility to use only what they require and potentially reduce costs to hospitals and ambulatory surgery centres.
Additionally, the pre-filled syringe saves the time and expenses related to mixing and preparing the agent.
GI Supply CFO and interim CEO Kristi Dahlke said: “The launch of EverLift 10ml completes our offering as now we have two separate presentations of lifting agents in a 5ml and 10ml syringe to give physicians more flexibility. We are committed to continuing to invest in innovation and this launch is another proof of our continuous investments.”
According to the company, EverLift device offers margin delineation of the lesions with darker blue colour compared to other existing submucosal lifting agents.
The darker colour will enable safe and complete polyp resections.
The company has used a cellulose-based formulation to make it hypertonic. It will form a lifting agent that is particularly formulated with water-retaining properties.
It results in a slower rate of absorption due to osmotic resistance. Slower absorption rate will provide gastroenterologists with a long lift during their resection procedures.
GI Supply specialises in endoscopy and paracentesis products for gastroenterologists, colorectal surgeons, and interventional radiologists.
Earlier this month, Laborie Medical Technologies acquired GI Supply in partnership with growth equity firm Signet Healthcare Partners.